Investors
Developing medicines
for CMD.
Lucier is a private biopharmaceutical company developing endotype-specific medicines for coronary microvascular dysfunction.
Our programs build on coronary arteriolar research to investigate CMD endotypes and the distinct mechanisms that may guide drug development.
Research funding
A $606,311 NIH award.
Advancing LU-1001.
Phase I STTR research award
Support from the National Heart, Lung, and Blood Institute (NHLBI) advances the investigation of LU-1001 in isolated coronary arterioles and a porcine model of CMD. Texas A&M University is the subaward institution.
- Lucier principal investigator
- Dr. Guangrong Lu
- Project period
- through
View the NIH award record (opens in a new tab)
Award 1R41HL184579-01A1
Investor enquiries
Let’s discuss what comes next.
For investment and strategic partnership enquiries.